Bone marrow stromal cell antigen 2 (BST2) suppresses the migration and invasion of trophoblasts in preeclampsia by downregulating matrix metallopeptidase 2 (MMP2)

Liu Jinyu a,b,c, Wang Shuying a, Zheng Panchan a, Chen Dan a, Chen Chao a,b,c, Yang Xingyu a,b, and Cheng Weiwei a

International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; a Shanghai Key Laboratory of Embryo Original Disease, Shanghai, China; a Institute of Birth Defects and Rare Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

ABSTRACT
Preeclampsia is a grievous pregnancy-related complication with an incidence of approximately 5~7% in pregnant women. Placental abnormalities and decreased placental perfusion associated with impaired trophoblast invasion are early pathological findings of preeclampsia. BST2 is a multifunctional transmembrane protein that plays critical roles in physiological and pathological processes, but its impacts and mechanisms of action in preeclampsia are inadequately understood. The aim of this manuscript was to investigate the functional impacts of BST2 and MMP2 on the biological behavior of trophoblast cells in preeclampsia. The expression of these proteins and their genes was analyzed by qRT-PCR, western blotting and immunohistochemistry. The results showed that the expression of BST2 and MMP2 was significantly downregulated in preeclampsia. The migration and invasion capacities of HTR-8/SVneo and JAR cells with overexpression or knockdown of BST2 were detected by wound healing assay and Transwell assays. It was found that BST2 overexpression could up-regulate MMP2 expression, and enhance the migration and invasion capacity of HTR-8/SVneo and JAR cells. BST2 knockdown could reverse these effects. MMP2 knockdown could downregulate the invasion capacity of HTR-8/SVneo cells, and MMP2 overexpression reversed these effects. Pearson correlation analysis demonstrated that the expression of MMP2 and BST2 were positively correlated. These results indicate that the downregulation of BST2 lowers MMP2 expression and restraints trophoblast functions, which probably explain its role in the pathogenesis of preeclampsia.
**Highlights**

- BST2 and MMP2 were downregulated in pre-eclamptic placental tissues.
- BST2 knockdown inhibited invasion and migration in HTR-8/SVneo and JAR cells.
- BST2 overexpression promoted invasion and migration in HTR-8/SVneo and JAR cells.
- BST2 modulated trophoblast invasion/migration behavior via MMP2.

**1. Introduction**

Preeclampsia (PE) is a multisystem disease that is characterized by the sudden appearance of hypertension and proteinuria after 20 weeks of pregnancy [1]. Preeclampsia is the main reason for enunciativ-premature delivery or fetal growth restriction, and causes more than 50,000 maternal deaths worldwide each year [2]. This syndrome is widely accepted as a two phase-disease: stage I is abnormal placenta formation in early pregnancy, and stage II refers to the clinical manifestations that directly lead to systemic endothelial activation. A poorly perfused placenta produces factors that result in systemic vascular disease and clinical symptoms. The pathological process of preeclampsia is accompanied by impaired placental trophoblast function, insufficient uterine spiral artery modification, and oxidative detriment [3]. At present, there is no particular treatment for preeclampsia, and placenta and fetus delivery are considered as the sole resolution. Early-pregnancy screening for preeclampsia and fetal growth restriction might afford the possibility of vigilant prenatal monitoring and appropriate fetal delivery to avert severe sequelae [4]. Thus, it is of tremendous importance to clarify the mechanism of preeclampsia and to identify new molecular targets that could meet the needs of early diagnosis and clinical treatment.

As an endocrine organ at the interface of fetus and mother, the placenta is crucial for fetal development [5]. The uterine vasculature withstands drastic adjustment to satisfy the nutritional needs of fetal development and growth, resulting in an increase in blood flow to the placenta [6]. Extravillous trophoblasts anchored in the uterine wall could migrate through the decidual stroma and gradually invade the uterine spiral artery under physiological conditions [7]. Extravillous trophoblasts might destroy the muscle layer and elastic tissue, replace vascular endothelial cells, and induce remodeling of uterine spiral arteries. Invasion by trophoblasts, reconstruction of the uterine vasculature and the development of the placenta are critical to determining the destiny of a pregnancy. Shallow trophoblast infiltration and low placental vascular network development are common characteristics of preeclampsia [8]. Uteroplacental insufficiency may lead to placental ischemia and oxidative stress. Some scientists believe that the malfunctioning of trophoblasts and placental injury might play essential roles in the development of preeclampsia [9]. Normal gene expression and regulation play pivotal roles in healthy pregnancy, as gene expression deviations are related to pathological processes, such as intrauterine growth restriction and preeclampsia. Trophoblasts highly express numerous transcription factors and related target genes that support their essential role in the development of preeclampsia.

Bone marrow stromal cell antigen 2 (BST2) is type II transmembrane protein composed of 180 amino acids, which is also named Tetherin or cluster of differentiation 317 (CD317) [10]. BST2 displays antiviral activity in vitro and vivo [11]. Its N-terminal transmembrane conformation and C-terminal glycolphosphatidylinositol (GPI) anchor can insert into the cell membrane to form a special topological structure. And the special structure of BST2 might be related to its functions and characteristics, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-xB) activation, virus confinement and endocytosis, glycosylation, ubiquitination, etc [12]. The cytoplasmic tail of BST2 comprises a highly conserved double-tyrosine motif YYX which is involved in BST2 endocytosis and NF-xB activation. Upregulation of BST2 expression is related to some tumor pathologies [13]. BST2 facilitates cell adhesion; promotes the expression of factors such as C-X-C motif chemokine receptor 4 (CXCR4), its ligand C-X-C motif chemokine ligand 12 (CXCL12), and matrix metalloproteinases (MMPs); and degrades proteases in the extracellular matrix [14]. Correlation studies performing meta-analyze of multiplex tumor datasets demonstrated that BST2 expression showed a positive correlation with the incursion of numerous cancers. BST2 overexpression enhances the migration, invasion, proliferation and growth capacity of carcinoma cells, while
anchor-independent growth, migration, and invasion are suppressed in BST2-knockdown carcinoma cells, though cell proliferation is not [13–15]. The greater tumor growth and metastasis with high BST2 levels might lead to poor prognosis and decreased patient survival rates [16].

MMPs are significant regulators of uterine remodeling and vascular construction [17–19]. Dysregulated MMP activity has been reported to be an important factor involved in clinical diseases affecting the cardiovascular system, including gestational hypertensive disorders, such as PE [18]. Increases expression/activity in MMP are involved in vasodilation, placenta formation, and uterine expansion in the course of physiological pregnancy [19]. Among the MMPs, MMP2 and MMP9 are believed to be activated in ischemic lesions and are critical for the progression of damage during and after ischemia [19–21]. Growing evidence suggested that MMP2 or MMP9 could work in the prediction or evaluation of PE [19,22]. MMP2 mainly exists as pro-MMP2 and activated MMP2 in cells, and pro-MMP2 can turn into activated MMP2 by chemical disruption or proteolytic cleavage. MMP2 is a key member of the MMP gelatinase family with increased expression associated with cell invasion due to its effects on degrading the extracellular matrix, which can accelerate cell growth and promote angiogenesis [17]. Decreased vascular MMP2 levels could lead to systemic vasomotor dysfunction, hypertensive pregnancy, and preeclampsia [23].

Our previous study demonstrated that BST2 expression was differentially expressed in human umbilical vein endothelial cells (HUVECs) between normal and PE pregnancies [24]. However, the expression of BST2 in the placenta of pregnant women with PE and its specific mechanism of action have not yet been reported. Dysregulation of MMP2 has been implicated in abnormal vasodilation, placentation, and uterine expansion in preeclampsia. There have been few studies on the relationship between BST2 and MMP2 in the pathogenesis of preeclampsia. Given the finding that BST2 might suppress the migration and invasion abilities of trophoblasts by downregulating MMP2 in preeclampsia, this study aimed to reveal the potential connection between BST2 and MMP2, evaluate the influence of BST2/MMP2 on chorionic trophoblast cell function and determine its possible mechanism in the PE process to provide an effective theoretical basis for studying the pathogenesis of preeclampsia.

2. Material and methods

2.1. Patient recruitment and tissue collection

This study was approved by the Ethics Committee of International Peace Maternity and Child Health Hospital (IPMCH), Shanghai, China. Twenty-four pregnant women with preeclampsia who gave birth from July 2019 to March 2021 in IPMCH were selected for the PE group. Sixteen pregnant women were recruited as the control group during the same period, who had no history of PE and no proteinuria and remained normotensive throughout pregnancy. The elective cesarean sections in the control group were done because of a breech delivery or previous cesarean section. All pregnant women underwent selective cesarean delivery. Placental samples were acquired immediately after delivery. Two pieces of placental tissue (approximately 1 cm³ each) were dissected from the maternal surface of the placentas (away from the umbilical cord attachment area, avoiding bleeding and calcification). Placental tissues were separated and stored at −80°C [24]. Preeclampsia was defined as hypertension with proteinuria (urinary protein > 300 mg/24 h) that occurred after 20 weeks of gestation [4]. Hypertension was defined as systolic blood pressure (SBP) > 140 mmHg or diastolic blood pressure (DBP) > 90 mmHg at two measurements 4 to 6 hours apart. Patients with severe kidney disease, primary or chronic hypertension, autoimmune disease, poor maternal history, liver disease, gestational diabetes, or other obstetric complications were excluded.

2.2. Cell culture and transfection

Human trophoblast cells (HTR-8/SVneo) were maintained in DMEM/F12 medium (HyClone, USA). Human choriocarcinoma cells (JAR) were cultured in RPMI-1640 medium (Biosharp, China). The medium used for cell culture was supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, USA) and 1% penicillin/streptomycin (Thermo Fisher Scientific). All cells were cultured in a humidified incubator (Thermo Fisher Scientific) at 37°C and 5% CO₂. Transfection was performed
Table 1. Primer and siRNA sequence.

| Gene   | 5'-3'                          |
|--------|--------------------------------|
| 18s    | F: GTACCCGTGAAACCCATT          |
|        | R: CCAATCATCGTGAACGGCT        |
| BST2   | F: AGGAGATGTTGGTGACATGGCG     |
|        | R: ATGGAAAGCGGGGATACAGG       |
| MMP2   | F: TGTTGTTCTCCAGAGGCAATG      |
|        | R: ATCAGTGCCAGCTGGTTG         |
| siRNA-BST2 | F: GCUCUGAUUCACUGUGAATT      |
|        | R: AAUCACGAUGAUCAGGACCTT      |
| Negative control | F: UUCUCGGAAGCUGUCAGUTT   |
|        | R: ACGUGACACGGGAGAATT         |
| siRNA-MMP2 | F: GUGGCCAUCUCACAUCUCUTT     |
| Negative control (MMP2) | F: AGAAGUUGUAGUUGGCCACTT |
|        | R: AGAAGUUGUAGUUGGCCACTT      |

24 hours after the cells were seeded in 6-well plates. Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific) was used for siRNA and vector transfection experiments. BST2 siRNA, MMP2 siRNA, negative control siRNAs (shown in Table 1), BST2 overexpression plasmids, MMP2 overexpression plasmids and empty control vectors were synthesized by GenePharma, China. The cells were used for the following experiments 48 h after transfection. All operations followed the manufacturer’s instructions [25].

2.3. RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)

According to the manufacturer’s protocol, total RNA of cells or tissues was isolated using TRIzol reagent (Thermo Fisher Scientific). RNA purity and concentration were detected by Nanodrop 2000 (Thermo Fisher Scientific). The Reverse Transcriptation Kit (Transgen, China) was used for total RNA reverse transcription into cDNA. The SYBR Green Kit was purchased from Transgen, China. The Q7 flex real-time PCR System was used for real-time polymerase chain reaction. The reaction system was as follows: 95°C for 30s, 40 cycles of 95°C for 5 s and 60°C for 30s, followed by melting curve analysis. 18S rRNA was selected as the internal reference, and the 2−ΔΔCt method was used for data analysis [25]. The sequences are shown in Table 1.

2.4. Western blot analysis

Radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific) was used to obtain protein extracts from human placentas and cell cultures. The concentration of the obtained protein sample was measured with a BCA protein determination kit (Thermo Fisher Scientific). The protein samples were separated by SDS-PAGE and then transferred to PVDF membranes. Five percent skimmed milk was used to block the membranes at room temperature for 1 hour, and then the membranes were incubated with antibodies (BST2 and MMP2 (Abcam, UK), GAPDH, β-actin and β-tubulin (Yeasen, China) at 4°C overnight. Corresponding horseradish peroxidase-conjugated secondary antibodies were added for incubation at room temperature for 1 hour. The color was developed by chemiluminescence (Bio-Rad, Germany), and the imaging results were analyzed with a gel imaging system [25].

2.5. Immunohistochemistry (IHC)

Mouse- and rabbit- specific HRP/DAB detection IHC kit (Abcam, UK) was used for immunohistochemistry. Briefly, fixed chorionic tissue was dehydrated with gradient alcohol, embedded, sectioned, deparaffinized and rehydrated, and then heated in EDTA buffer for antigen retrieval. After incubation overnight with primary antibodies diluted in PBS (anti-BST2 antibody 1:300, anti-MMP2 antibody 1:200) at 4°C, they were washed with PBS four times and incubated with corresponding secondary antibodies [26]. The slides were stained with DAB chromogen and counterstained with hematoxylin, and images were captured by a Leica DMi8 microscope (Leica Microsystems, Germany).

2.6. Wound healing assay

HTR8/SVneo cells transfected for 48 hours (siRNAs or vectors) were trypsinized and seeded in Petri dishes to reach 90% confluence. Sterile 10 µL pipette tip was used to scratch the cells. The scratched cells were washed 3 times with PBS. The stale medium was replaced with fresh serum-free medium. The scratched area was photographed under the microscope at 0, 12, and 24 hours for subsequent calculation of wound healing [25].
Table 2. Clinicopathological features of healthy pregnant and PE women.

|                         | Control (CON, n = 16) | Preeclampsia (PE, n = 24) | p Value |
|-------------------------|-----------------------|---------------------------|---------|
| Maternal age (years)    | 24 ~ 39               | 27 ~ 44                   | 0.129   |
| BMI (kg/m²)             | 22 ± 3                | 22 ± 3                    | 0.730   |
| Gestational age (days)  | 273 ± 5               | 247 ± 23                  | <0.001  |
| Birth weight (g)        | 3366 ± 429            | 2228 ± 803                | <0.001  |
| Placental weight (g)    | 608.00 ± 79.54        | 468.75 ± 138.26           | <0.001  |
| Neonatal body length    | 49.75 ± 1.29          | 45.92 ± 3.66              | <0.001  |
| Proteinuria (g/24 h)    | Not detected          | 1.09 ± 0.85               | -       |
| SBP (mm/Hg)             | 114 ± 8               | 152 ± 16                  | <0.001  |
| DBP (mm/Hg)             | 73 ± 7                | 97 ± 11                   | <0.001  |

2.7. Transwell assay

The migration and invasion capacities of HTR-8/SVneo and JAR cells were determined with 8 µm Transwell filters (Corning, USA). The transfected cells were resuspended in serum-free medium and added to the upper chambers of the Transwell. Medium containing 20% FBS was added to the lower chambers. In the migration assay, the cells were incubated for 24 hours at 37°C in 5% CO₂ atmosphere and allowed to migrate to the bottom of the well. These cells were fixed with 4% paraformaldehyde and then stained with crystal violet [25]. In the invasion test, the upper chamber was coated with diluted Matrigel (BD Biosciences, USA), and after 48 hours of culture, the

Figure 1. BST2 was decreased in the placental tissue of preeclampsia patients. (a) The mRNA expression level of BST2 in the placental tissues of preeclamptic patients (PE) and normal controls (CON) was determined using qRT-PCR, CON = 16, PE = 24, (b) Representative western blotting image of BST2 in placental tissue samples and quantification of its expression normalized to β-actin in placentas. (CON: C1, C2, C3; PE: P1, P2, P3). (c) Representative images from immunohistochemical analysis of BST2 expression in human placentas (under preeclampsia and not). Original magnification: × 200; Scale bar: 100 µm. Data are shown as the mean ± SD from three independent experiments. Statistical significance was calculated by Student’s t test. *p < 0.05, **p < 0.01.

2.8. Statistical analysis

SPSS 23.0 statistical software, ImageJ and GraphPad Prism 8 were used for data analysis and chart production. Student’s t tests were performed to evaluate the differences. The results are shown as mean ± SD. Pearson’s Correlation coefficient was calculated to analyze the relationship between BST2 and MMP2 expression. Differences were considered statistically significant when p < 0.05.

3. Results

This study aimed to investigate the BST2/MMP2 axis mediates abnormal trophoblast functions in the pathogenesis of PE. We started by analyzing the expression of BST2 and MMP2 in PE placentas. Then, the BST2 effects on the migration and invasion of chorionic trophoblast cells were detected by transfecting siRNAs or overexpression vectors into HTR-8/SVneo and JAR cells. Thereafter, it was indicated that MMP2 was
downstream of BST2. Rescue experiments were conducted by up-regulating and down-regulating MMP2. Our results revealed that lower expression of BST2 reduces MMP2 expression and restrains the migration and invasion capacity of trophoblasts.

3.1. Subject characteristics

The characteristics of the patients enrolled in this study are presented in Table 2. Maternal age and body mass index (BMI) were similar between the control and PE groups. The gestational age and placental weights at delivery were significantly lower in PE patients than controls. The birth weight and body length of newborns were also lower in the PE groups. Blood pressure and proteinuria in preeclamptic women were significantly higher than those of controls.

3.2. BST2 and MMP2 expression in PE placentas

To determine whether BST2 and MMP2 are involved in the pathogenesis of PE, the mRNA expression of these genes was determined by qRT-PCR. BST2 was significantly lower in the placenta of the PE group (PE) than the control group (CON) (Figure 1(a), p < 0.05). The MMP2 mRNA level was significantly lower in the PE group (PE) than the control group (CON) (Figure 4(a), p < 0.05). BST2 protein expression was determined by immunoblotting experiments, and lower BST2 expression was found in the PE group than in the control group (CON) (Figure 1(b), p < 0.05). The MMP2 protein level was significantly lower in the PE group (PE) than the control group (CON) (Figure 4(b), p < 0.05). The results are presented as the mean ± SD. *p < 0.05.
lower in the PE group than the control group (CON) (Figure 4(b), \( p < 0.05 \)). BST2 was predominantly expressed on the lateral trophoblast cytomembrane in third-trimester placental tissue, as confirmed by immunohistochemical experiments, and was expressed at lower levels in the PE group than in the control group (Figure 1(c), \( p < 0.01 \)). The immunohistochemical results showed that MMP2 was mainly expressed in the cytoplasm of syncytiotrophoblasts, and MMP2 expression was significantly downregulated in the PE group (Figure 4(c), \( p < 0.05 \)). The expression of BST2 and MMP2 in trophoblast cells of PE patients was decreased, which suggested that they were involved in trophoblast cell dysfunction in the course of PE.

### 3.3. BST2 influenced trophoblast invasion and migration ability

To determine the role of BST2 during PE, HTR-8/SVneo and JAR cells were transfected with siRNA or overexpression plasmids. The data showed that siRNA-BST2 significantly downregulated BST2 (Figure 2(a-c), \( p < 0.05 \)), so it was used for subsequent experiments. Knockdown of BST2 significantly suppressed the migration of HTR-8/SVneo cells in the Transwell migration experiment (Figure 2(d), \( p < 0.05 \)). This was consistent with the results of the wound healing assay (Figure 2(e), \( p < 0.05 \)), which revealed that the knockdown of BST2 significantly inhibited the migration abilities of HTR-8/SVneo
3.4. BST2 might regulate MMP2 expression in preeclampsia

BST2 (Figure 1) and MMP2 (Figure 4) expression were both downregulated in trophoblasts of PE placentas and BST2 seemed to have a notable influence on HTR-8/SVneo migration and invasion (Figure 2, Figure 3). The expression of MMP2 and MMP9 was also examined in BST2 downregulated HTR8/SVneo cells. The results showed that BST2 may not affect trophoblast cell migration through MMP9 (data not shown) but rather through MMP2. Our data revealed that the mRNA level (Figure 5(a)) and protein expression (Figure 5(b,c)) of MMP2 were downregulated in BST2-knockdown cells and upregulated in BST2-overexpressing cells. Moreover, according to the Pearson correlation coefficient, the expression of BST2 was positively correlated with MMP2 in placental tissues from PE women (Figure 5(d)). These data indicated that BST2 might regulate MMP2 expression in PE placental trophoblast cells.

3.5. MMP2 influenced the invasion ability of HTR-8/SVneo cells

The siRNA-MMP2 significantly induced MMP2 downregulation (Figure 6(a-c), p< 0.01) and significantly suppressed the invasion capacity of HTR-8/SVneo cells (Figure 6(d)). The MMP2-overexpression plasmid significantly upregulated MMP2 expression levels (Figure 6(a,b), p< 0.05) and improved cell invasion in HTR-8/SVneo trophoblast cells (Figure 6(d)). The relative cell quantification is...
shown in Figure 6(e). These data demonstrated that MMP2 might play a part in PE through its action in placental trophoblast cells.

3.6. BST2 could regulate the migration and invasion of trophoblast cells via MMP2

To study how MMP2 and BST2 function during PE progression, we performed cell rescue experiments. The results showed that upregulating MMP2 partly reversed the suppressive effect of BST2 downregulation on the migration and invasion of HTR-8/SVneo cells (Figure 7(a-c)), while upregulating BST2 drastically reversed the suppressive effect of MMP2 downregulation on the migration and invasion of HTR-8/SVneo cells (Figure 8(a-c)), demonstrating that BST2 significantly affected the function of MMP2 in trophoblasts.

4. Discussion

Preeclampsia poses great threats to maternal and fetal health. PE leads to a great burden on patients, their families and society. And the burden is physical, psychological and economic in nature. The pathogenesis of preeclampsia is complex and still being intensely investigated, and placental dysfunction has been identified as a hallmark of preeclampsia [28]. It has been observed that decidual injury increases the invasive potential of trophoblast cells. In the case of preeclampsia, trophoblast cells are often damaged, leading to characteristic placental hypoperfusion [9]. This research focused on the association between abnormal placental development and insufficient trophoblast invasion of PE. We examined BST2 expression in PE and normal placental tissues and found that the expression of BST2 was notably lower in PE placentas. Considering the difference in gestational age between the control group and PE patients, the effect of gestational age on BST2 expression was investigated (Figure S1). The results showed that BST2 expression was not affected by gestational age. Further exploring the molecular mechanism of BST2 in PE, we found a restraining effect of the downregulation of BST2 expression on the invasion and migration of trophoblasts, indicating that BST2 downregulation might be associated with PE.
Multiple theories have been proposed to explain the occurrence of preeclampsia. Existing studies have shown that insufficient invasion of trophoblasts in early pregnancy might lead to preeclampsia [29,30]. A growing number of studies have shown the existence of transcriptome disparities between the placenta in uncomplicated and PE pregnancies [31]. In our previous studies, we explored the role of endothelial dysfunction in the pathogenesis of preeclampsia through microarray analysis and found that BST2 was differentially expressed in HUVECs from PE patients compared with non-PE patients [24]. Previous studies have indicated that BST2 is upregulated in some malignant tumors. High expression of BST2 contributes to a poor prognosis in patients with oral cavity, esophageal, gastric or colorectal cancer [16,32,33], indicating that highly-expressed BST2 might promote tumor growth and metastasis. For example, down-regulated BST2 expression could suppress gastric cancer in vivo [34]. It is worth noting that BST2 promotes cell migration and invasion of many cancers, which is consistent with our findings in trophoblasts. Here, BST2 promoted HTR-8/SVneo and JAR cell migration and invasion abilities, and BST2 knockdown reversed these effects. Moreover, proliferation and apoptosis assays did not reveal profound differences between BST2-transfected cells and control cells (data not shown). Migration and invasion are essential functions of trophoblasts during pregnancy. Trophoblast migration is an important process that accompanies differentiation and invasion into the maternal decidua. When trophoblasts invade the decidua, the maternal spiral arteries efficiently supply nutrients to the developing fetus [35,36]. Pregnancy always involves the growth of an allograft, and trophoblast cells steer clear of immune rejection and invade maternal placenta [37]. The fetal-maternal immunological interface consists of maternal decidual cells (developed from the endometrium) and fetal trophoblast cells [38]. Abnormal placental development caused by trophoblast dysfunction might lead to severe gynecological diseases and...

Figure 6. Silencing MMP2 inhibited invasion by HTR8/SVneo cells, and overexpression of MMP2 reversed this effect. Transfection efficiency was detected by qRT-PCR and western blotting. Relative MMP2 mRNA levels were detected by qRT-PCR in HTR-8/SVneo cells (a) transfected with MMP2 overexpression plasmid (MMP2), blank plasmid (empty vector, EV), MMP2 siRNA (si-MMP2) or control siRNA of MMP2 (si-NC[MMP2]). Western blotting was performed to detect MMP2 protein levels in HTR8/SVneo cells (B&C). Representative images of cell invasion detected by Transwell assay (d) and relative cell quantification of HTR-8/SVneo cells (e). Original magnification, ×200. The results are presented as the mean ± SD. *p< 0.05, **p< 0.01, ***p< 0.001.
fetal malformations. Thus, we speculate that trophoblast dysfunction after BST2 downregulation might be involved in placental dysfunction pathogenesis. Given the important biological roles of trophoblasts in normal pregnancy and preeclampsia, our results provide the basis for this.

To explore how BST2 acts in trophoblasts, previous studies and the STRING database (https://string-db.org) were searched to find potential genes [39]. qRT-PCR and western blot analysis were used to investigate their mRNA and protein expression levels. We found that MMP2 was decreased in PE placentas and that MMP2 expression was lower in BST2 siRNA-transfected cells than in control cells. Studies have shown the latent pathway by which BST2 exerts its biological functions, which involves regulating MMP2 activities. MMP2 has been found to inhibit cell adhesion, invasion, and migration. MMPs are vital in regulating vascular formation and uterine spiral artery remodeling [40,41]. Here, MMP2 expression was higher in BST2 overexpressing plasmid-transfected cells than in control cells. It is worth noting that this interaction has been reported in MDCK cells and HT1080 cells [42]. Our experiments confirmed this interaction and revealed that BST2 promoted the expression and activity of MMP2 in trophoblasts. The results of rescue experiments showed that MMP2 overexpression reversed the inhibition of immigration and invasion induced by BST2 decline in HTR-8/SVneo cells, while upregulation of BST2 prevented the inhibitory effect of MMP2 downregulation on the migration and invasion capacities of HTR-8/SVneo cells, demonstrating that BST2 can significantly affect the function of MMP2 in trophoblasts. Abnormal expression of factors such as uterine-placenta integrin, cytokines, and MMPs,
could cause maternal tolerance reduction, invasive trophoblast cell apoptosis, incomplete spiral artery remodeling, and reduced uterine perfusion pressure [43]. Reduced uterine perfusion pressure might stimulate inflammatory cytokine and hypoxia-inducible factor release and cause an imbalance of circulating factors, such as soluble Fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) [44,45]. MMP2 and MMP9 are the main MMPs expressed in placental tissues. Increases in MMP2 and MMP9 expression are implicated in placentation, vasodilation, and uterine expansion during physiological gestation [19], whereas, decreased vascular MMP2 might lead to vasodilation decrease, vasoconstriction increase, and hypertensive disorder, resulting in PE. The literature has shown that MMP2 is a crucial factor in the biological functions of trophoblasts, such as migration, invasion and proliferation [46]. Knockdown of MMP2 in trophoblasts might reduce cell growth, proliferation and invasion via the extracellular signal-regulated protein kinases (Erk)/pErk pathway [47]. Our data revealed upregulation of MMP2 mRNA and protein levels in BST2-overexpressing trophoblast cells, as well as downregulation of MMP2 mRNA and protein levels in BST2 knockdown trophoblast cells. Therefore, MMP2 might play a central role in mediating the protective role of BST2. The decrease in MMP2 expression can be detrimental to deteriorated pregnancy such as a PE pregnancy.

We found that MMP2 expression is downregulated in placental tissues of preeclampsia and might be upregulated by BST2 which might promote the migration and invasion of trophoblast cells. In addition, the correlation

Figure 8. BST2 upregulation improved the decline in cell invasion and migration due to MMP2 downregulation in HTR-8/SVneo cells. Transfection efficiency was detected by qRT-PCR and western blotting. Relative MMP2 mRNA levels were detected by qRT-PCR in HTR-8/SVneo cells (a) transfected with BST2 overexpression plasmid (BST2), blank plasmid (VECTOR), MMP2 siRNA (si-MMP2) or control siRNA of MMP2 (si-NC(MMP2)). Western blotting was performed to detect MMP2 protein levels in HTR8/SVneo cells (b). Representative images of cell invasion/migration detected by Transwell assay and relative cell quantification of HTR-8/SVneo cells (c), original magnification, ×200. The results are presented as the mean ± SD. *p < 0.05, **p < 0.01.
analysis demonstrated that the MMP2 level is positively correlated with the expression of BST2. Therefore, we thought that inhibition of BST2 expression and activity could exacerbate preeclampsia, because it might cause trophoblast dysfunction by inhibiting MMP2 expression. The findings indicated that BST2 regulates the expression of MMP2 in trophoblasts of PE placentas.

There are still some limitations in this work. One is that rat PE model should be established to study the role of BST2 in vivo. Two is that patient blood samples need to be collected to study the plasma BST2 concentration and further validate our research findings. In addition, it has been reported that IFN and MT-I-MMP might be involved in the transcriptional regulation of BST2, by interfering with the expression of these molecules in HTR8/Svneo cells, so upstream effects need to be verified based on the influence of genes on cell function. The current study was based on commercial cell lines, which are dissimilar to normal trophoblasts. Therefore, investigation of primary trophoblast cells might verify our conclusion.

5. Conclusion

In summary, we found that BST2 and MMP2 were decreased in the placentas of preeclampsia patients. BST2 mediates trophoblast migration and invasion by upregulating MMP2 expression. Our findings suggested that BST2 can be chosen as a new target and is a potential biomarker for PE. Further in vitro/in vivo experiments and mechanistic explorations are needed to understand PE pathogenesis thoroughly and provide novel approaches to cure the disease.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This study was sponsored by the Scientific Research Project Plan of Shanghai Health Commission (20210091), the project support the guidance of medicine (Traditional Chinese and Western medicine) in Shanghai (18411963500), the National Natural Science Foundation of China (81370727 and 81501256), and the interdisciplinary programme of Shanghai Jiao Tong University (ZH2018ZDA31); the interdisciplinary program of Shanghai Jiao Tong University the interdisciplinary program of Shanghai Jiao Tong University [ZH2018ZDA31];

Author contribution statement

JY L, XY Y and WW C conceived and designed the experiments, SY W, JY L, PC Z, D C and C C collected samples, JY L, D C and C C performed the experiments. JY L and X-Y Y analyzed the data and wrote the manuscript, XY Y and WW C contributed reagents and materials and to revised the manuscript.

Ethics approval and consent to participate

The present study was approved by the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University Experimental Ethics Committee (Shanghai, China). Approval code: (GKLW)2018-07. Written informed consent was provided by all patients.

ORCID

Liu Jinyu http://orcid.org/0000-0003-0318-1663
Cheng Weiwei http://orcid.org/0000-0002-0805-8296

References

[1] Mol BWJ, Roberts CT, Thangaratinam S, et al. Preeclampsia. Lancet. 2016;387(10022):999–1011.
[2] Rana S, Lemoine E, Granger JP, et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–1112.
[3] Ives CW, Sinkey R, Rajapreya L, et al. Preeclampsia-Pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(14):1690–1702.
[4] ACOG practice bulletin No. 202: gestational hypertension and preeclampsia [J]. Obstet Gynecol. 2019;133(1):1.
[5] Gingrich J, Ticiani E, Veiga-Lopez A. Placenta disrupted: endocrine disrupting chemicals and pregnancy. Trends Endocrinol Metab. 2020;31(7):508–524.
[6] Sato Y. Endovascular trophoblast and spiral artery remodeling. Mol Cell Endocrinol. 2020;503:110699.
[7] Abbas Y, Turco MY, Burton GJ, et al. Investigation of human trophoblast invasion in vitro. Hum Reprod Update. 2020;26(4):501–513.
[8] Staff AC, Fjeldstad HE, Fosheim IK, et al. Failure of physiological transformation and spiral artery atherosclerosis: their roles in preeclampsia. Am J Obstet Gynecol. 2022;225(25):S895–S906.
[9] Ridder A, Giorgione V, Khalil A, et al. Preeclampsia: the relationship between uterine artery blood flow and trophoblast function. Int J Mol Sci. 2019;20(13):3263.
[10] Sauter D. Counteraction of the multifunctional restriction factor tetherin. Front Microbiol. 2014;5:163.
[11] Neil SJ. The antiviral activities of tetherin. Curr Top Microbiol Immunol. 2013;371:67–104.
[12] Buffalo CZ, Stürzel CM, Heusinger E, et al. Structural basis for tetherin antagonism as a barrier to zoonotic lentiviral transmission. Cell Host Microbe. 2019;26(3):359–368.e8.
[13] Tiwari R, de la Torre JC, McGavern DB, et al. Beyond tethering the viral particles: immunomodulatory
functions of tetherin (BST-2). DNA Cell Biol. 2019;38 (11):1170–1177.

[14] Mahaud-Fernandez WD, Okeoma CM. The role of BST-2/Tetherin in host protection and disease manifestation. Immun Inflamm Dis. 2015;4(1):4–23.

[15] Świecki M, Omttage NS, Brett TJ. BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor. Mol Immunol. 2013;54(2):132–139.

[16] Mukai S, Oue N, Oshima T, et al. Overexpression of transmembrane protein BST2 is associated with poor survival of patients with esophageal, gastric, or colorectal cancer. Ann Surg Oncol. 2017;24(2):594–602.

[17] Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739.

[18] Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018;81:241–330.

[19] Chen J, Khalil RA. Matrix metalloproteinases in normal pregnancy and preeclampsia. Prog Mol Biol Trans Sci. 2017;148:87–165.

[20] Busti C, Falcinelli E, Momi S, et al. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 2010;5(1):13–25.

[21] Misra S, Talwar P, Kumar A, et al. Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: a systematic review and meta-analysis of 29 studies. Gene. 2018;672:180–194.

[22] Nikolov A, Popovski N. Role of gelatinases MMP-2 and MMP-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers. Diagnostics (Basel). 2021;11(3):480.

[23] Espino Y, Sosa S, Flores-Pliego A, et al. New insights into the role of matrix metalloproteinases in preeclampsia. Int J Mol Sci. 2017;18(7):1448.

[24] Chen D, He B, Zheng P, et al. Identification of mRNA-, circRNA- and IncRNA- associated ceRNA networks and potential biomarkers for preeclampsia from umbilical vein endothelial cells. Front Mol Biosci. 2021;8:652250.

[25] Xueya Z, Yamei L, Sha C, et al. Exosomal encapsulation of miR-125a-5p inhibited trophoblast cell migration and proliferation by regulating the expression of VEGFA in preeclampsia. Biochem Biophys Res Commun. 2020;525(3):646–653.

[26] Shen H, Zhao X, Li J, et al. Severe early-onset PE with or without FGR in Chinese women. Placenta. 2020;101:108–114.

[27] Zhang Q, Wang Z, Cheng X, et al. IncRNA DANCPR promotes the migration and invasion of trophoblast cells through microRNA-214-5p in preeclampsia. Bioengineered. 2021;12(2):9424–9434.

[28] Burton TJ, Jauhiaus E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S745–S761.

[29] Kieckbusch J, Gaynor LM, Moffett A, et al. MHC-dependent inhibition of uterine NK cells impedes fetal growth and decidual vascular remodelling. Nat Commun. 2014;5(1):3359.

[30] Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022;226(2):S108–S119.

[31] Awamleh Z, Gloor GB, Han VKM. Placental microRNAs in pregnancies with early onset intrauterine growth restriction and preeclampsia: potential impact on gene expression and pathophysiology. BMC Med Genomics. 2019;12(1):91.

[32] Fang KH, Kao HK, Chi LM, et al. Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer. Laryngoscope. 2014;124(9):E354–60.

[33] Cai D, Cao J, Li Z, et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 2009;9(1):102.

[34] Liu W, Li Y, Feng S, et al. MicroRNA-760 inhibits cell viability and migration down-regulating BST2 in gastric cancer. J Biochem. 2020;168(2):159–170.

[35] Vento-Tormo R, Efremova M, Bottig RA, et al. Single-cell reconstruction of the early maternal-fetal interface in humans. Nature. 2018;563(7731):347–353.

[36] Staud F, Karahoda R. Trophoblast: the central unit of fetal growth, protection and programming. Int J Biochem Cell Biol. 2018;105:35–40.

[37] Kim CJ, Romero R, Chaemsathanong P, et al. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol. 2015;213(4):S53–69.

[38] Makrigiannakis A, Karamouti M, Drakakis P, et al. Fetomaternal immunotolerance. Am J Reprod Immunol. 2008;60(6):482–496.

[39] Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–D368.

[40] Rohani MG, Parks WC. Matrix remodeling by MMPs during wound repair. Matrix Biol. 2015;44:46–113–121.

[41] Qu H, Khalil RA. Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia. Am J Physiol Heart Circ Physiol. 2020;319(3):H661–H681.

[42] Fan L, Liu L, Zhu C, et al. MT1-MMP inhibits the activity of Bst-2 via their cytoplasmic domains dependent interaction. Int J Mol Sci. 2016;17(6):818.

[43] Lin C, He H, Cui N, et al. Decreased uterine vascularization and uterine arterial expansive remodeling with reduced matrix metalloproteinase-2 and −9 in hypertensive pregnancy. Am J Physiol Heart Circ Physiol. 2020;318(1):H165–H180.

[44] Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.

[45] Spradley FT, Tan AY, Joo WS, et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension. 2016;67(4):740–747.

[46] Tian FJ, Cheng YX, Li XC, et al. The YY1/MMP2 axis promotes trophoblast invasion at the maternal-fetal interface. J Pathol. 2016;239(1):36–47.

[47] Pan S, Zhang Z, Li C, et al. Interleukin-25 regulates matrix metalloproteinase-2 and −9 expression in periodontal fibroblast cells through ERK and P38MAPK pathways. Cell Biol Int. 2020;44(11):2220–2230.